Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

29 August 2008

The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century

Maneesh N. Singh, Pierre L. Martin-Hirsch, Francis L. Martin

Med Sci Monit 2008; 14(9): RA144-148 :: ID: 867954

Abstract

Tamoxifen is a selective oestrogen receptor modulator (SERM) with an established role in the treatment and chemoprevention of hormone-related breast cancer. It is also cardioprotective and increases bone mineral density. However, due to pleiotrophic ligand-receptor properties, its role in a variety of seemingly unrelated disorders, including multiple sclerosis, Parkinson's disease, Alzheimer's disease, systemic lupus erythematosus and urological cancers, has been investigated in many studies. The non-patented drug tamoxifen confers a significant advantage over newer drugs in being inexpensive and well-tolerated with a known side-effect profile. This review highlights the interaction of tamoxifen on oestrogen receptors (ERs) and assesses whether this agent continues to have future applications in a variety of clinical settings, both as a therapy in early and established disease and usage as a prophylactic in those at risk of debilitating conditions. Indeed, it may have as-yet-unknown benefit(s) in a variety of conditions, both as a prophylactic in those at high-risk and also as in novel therapeutic strategies in established disease. Future clinical studies may seek to establish the exact future role and efficacy for SERMs both in men and women. Perhaps a multi-functional SERM such as tamoxifen may be the aspirin of the 21(st) century.

Keywords: Urinary Bladder Neoplasms - drug therapy, Tamoxifen - therapeutic use, Selective Estrogen Receptor Modulators - therapeutic use, Receptors, Estrogen - metabolism, Prostatic Neoplasms - drug therapy, Parkinson Disease - drug therapy, Neurodegenerative Diseases - drug therapy, Breast Neoplasms - drug therapy, Autoimmune Diseases - drug therapy

Add Comment 0 Comments

Editorial

01 May 2024 : Editorial  

Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)

Dinah V. Parums

DOI: 10.12659/MSM.944927

Med Sci Monit 2024; 30:e944927

In Press

Database Analysis  

Long-Term Prognosis of Patients Undergoing Percutaneous Coronary Intervention: The Impact of Serum Creatini...

Med Sci Monit In Press; DOI: 10.12659/MSM.943063  

Database Analysis  

Maternal Exposure to Environmental Air Pollution and Premature Rupture of Membranes: Evidence from Southern...

Med Sci Monit In Press; DOI: 10.12659/MSM.943601  

Animal Research  

Enhanced Bone Healing Through Systemic Capsaicin Administration: An Experimental Study on Wistar Rats

Med Sci Monit In Press; DOI: 10.12659/MSM.942485  

Clinical Research  

Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Co...

Med Sci Monit In Press; DOI: 10.12659/MSM.944052  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750